EFFECT OF A BENZOIC ACID DERIVATIVE ON THE DEVELOPMENT OF EXPERIMENTAL CHRONIC HEART FAILURE

Download full text PDF
DOI: https://doi.org/None
Issue: 
4
Year: 
2016

D.Yu. Ivkin (1,3), PhD; A.A. Karpov (2,3); A.V. Dracheva (2); N.N. Pitukhina (1); A.S. Ivkina (1); A.V. Buryakina (1), PhD; A.A. Teslev (1) 1 -Saint Petersburg State Chemopharmaceutical Academy; 14, Prof. Popov St., Saint Petersburg 197376, Russian Federation; 2 -Academician I.P. Pavlov First Saint Petersburg State Medical University; 6-8, Lev Tolstoy St., Saint Petersburg 197022, Russian Federation; 3 -V.A. Almazov Federal Medical Research Center, Ministry of Health of Russia; 2, Akkuratov St., Saint Petersburg 197341, Russian Federation

Background. Chronic heart failure (CHF) is the most common complication of many heart diseases; the most common one of them is coronary heart disease (CHD). CHF is characterized by periodical recurrent exacerbation episodes (decompensations) that appear as a sudden or gradual worsening of symptoms (dyspnea, ankle swelling, fatigue, and poor exercise tolerance) and signs (cervical vein swelling, small bubbling rales, etc.). Objective: to evaluate the effect of 4-(oxo-3-ethoxypropanamide)benzoic acid on the development of experimental post-infarction chronic heart failure. Material and methods. A chronic heart failure model was reproduced by ligation of the left coronary artery in outbred male rats (post-infarction chronic heart failure). The cardiotropic effect of an aminobenzoic acid derivative was studied comparing with reference drugs (methylethylpyridinol, meldonium, trimetazidine). The criterion of efficiency was the estimation of cardiac morphofunctional parameters, which was made by electroand echocardiography. Experimental cardiac ultrasonography was carried out 35 days after ligation of the left coronary artery with a nultifunctional MyLabTMTouch 8100 scanner having a SL 3116 linear transducer. Results. The magnitude of the cardiotropic effect of the test substance proved to be comparable with that of methylethylpyridinol, meldonium, and trimetazidine. The incorporation of the aminobenzoic acid derivative prevented the formation of intracardiac thrombi, aneurysms, and the development of the phenomena of myocardial asynergy and akinesia. Conclusion. The optimal route of administration of the aminobenzoic acid derivative was ascertained to be its parenteral injection in the acute phase of ischemic lesion (for 7 days), by switching to its oral intake at a dose of 60 mg/kg) (for 28 days or longer).
Keywords: 
myocardial ischemia
echocardiography
methylethylpyridinol
meldonium
trimetazidine
References: 
  1. Karpov A.A., Ivkin D.Yu., Dracheva A.V., Pituhina N.N. i dr. Modelirovanie postinfarktnoy serdechnoy nedostatochnosti putem okklyuzii levoy koronarnoy arterii u krys: tehnika i metody morfofunkcional`noy ocenki. Biomedicina, 2014; 3: 32–48. [Karpov A.A., Ivkin D.Yu., Dracheva A.V., Pitukhina N.N. et al. Rat model of post-infarct heart failure by left coronary artery occlusion: technical aspects, functional and morphological assessment. Biomedicine, 2014; 3: 32–48] (in Russian).
  2. Experimental Surgical Models in the Laboratory Rat. CRC Press Tayler &Fracis Group Boca Raton London New York, 2009; 252.
  3. Rukovodstvo po provedeniyu doklinicheskih issledovaniy lekarstvennyh sredstv. (pod red. Mironova A.N.). Chast`1. M.: Grif i K, 2012; 944. [Guidelines for preclinical studies of drugs. (ed. Mironov A.N.) Part 1. Moscow: Grif & K, 2012; 944] (in Russian).
  4. Kazachenko A.A., Okovityy S.V., Kulikov A.N., Gustaynis K.R. i dr. Sravnitel`naya harakteristika nekotoryh farmakologicheskih modeley hronicheskoy serdechnoy nedostatochnosti. E`ksper. i klin. farmakologiya, 2008; 71. (6): 16–19. [Kazachenko A.A., Okovityi S.V., Kulikov A.N., Gustainis K.R. et al. Comparative characteristics of some pharmacological models of chronic heart failure. Eksperimental’naya i klinicheskaya farmakologiya,2008; 71. (6): 16–19] (in Russian).
  5. Slama M., Susic D., Varagic J., Frohlich E.D. Echocardiographic measurement of cardiac output in rats. Am.J.Physiol. Heart.Circ. Physiol., 2003; 284: 691–97.
  6. Watson L.E., Sheth M., Denyer R.F., Dostal D.E. Baseline Echocardiographic Values For Adult Male Rats. J. Am. Soc. Echocardiogr., 2004; 17:161–7.
  7. Wasmeier G.H., Zimmermann W-H., Schineis N., Melnychenko I. et al. Real-time myocardial contrast echocardiography for assessing per-fusion and function in healthy and infarcted wistar rats. Ultrasound in med. & biol., 2008; 34. (1): 47–55.
  8. Geyer H., Caracciolo G., Abe H., Wilansky S. et al. Assessment of myocardial mechanics using speckle tracking echocardiography: fun-damentals and clinical applications. J. Amer. Soc. Echocardiogr., 2010; 23: 351–369.